Associations with NHL for baseline serum concentrations of selected immune and inflammation markers, overall and stratified by median time from blood collection to case diagnosis
| Analyte concentration (pg/mL)* . | . | . | . | Years from blood collection to case diagnosis . | ||
|---|---|---|---|---|---|---|
| Overall . | 5-7 . | 8-13 . | ||||
| NCont/NCase . | OR† (95% CI) . | NCont/NCase . | OR† (95% CI) . | NCont/NCase . | OR† (95% CI) . | |
| BCA-1 | ||||||
| <12.44 | 76/52 | 1.0 | 29/28 | 1.0 | 47/24 | 1.0 |
| 12.44-15.56 | 75/52 | 1.0 (0.6-1.6) | 36/26 | 0.8 (0.4-1.7) | 39/26 | 1.1 (0.6-2.3) |
| 15.57-20.15 | 75/61 | 1.3 (0.8-2.1) | 46/29 | 0.6 (0.3-1.4) | 29/32 | 2.2 (1.1-4.6) |
| ≥20.16 | 75/136 | 2.7 (1.7-4.2) | 42/70 | 1.7 (0.9-3.5) | 33/66 | 3.7 (1.9-7.2) |
| Ptrend‡ | 1.0 × 10−6 | .007 | 3.8 × 10−5 | |||
| sTNFR2 | ||||||
| <4021.67 | 76/45 | 1.0 | 37/25 | 1.0 | 39/20 | 1.0 |
| 4021.67-4896.02 | 75/52 | 1.3 (0.8-2.3) | 36/22 | 1.0 (0.5-2.2) | 39/30 | 1.7 (0.8-3.6) |
| 4896.03-5792.83 | 75/82 | 2.1 (1.2-3.5) | 37/42 | 2.0 (1.0-4.3) | 38/40 | 2.2 (1.0-4.6) |
| ≥5792.84 | 75/122 | 3.4 (2.0-5.8) | 43/64 | 3.1 (1.4-6.7) | 32/58 | 3.8 (1.8-8.1) |
| Ptrend | 1.1 × 10−6 | .001 | .0003 | |||
| TNF-α | ||||||
| <4.07 | 76/68 | 1.0 | 39/32 | 1.0 | 37/36 | 1.0 |
| 4.07-5.03 | 75/41 | 0.6 (0.4-1.1) | 34/21 | 0.8 (0.4-1.7) | 41/20 | 0.5 (0.2-1.0) |
| 5.04-6.35 | 75/74 | 1.2 (0.7-1.9) | 35/40 | 1.4 (0.7-2.8) | 40/34 | 0.5 (0.2-1.0) |
| ≥6.36 | 75/118 | 1.8 (1.1-2.9) | 45/60 | 1.7 (0.9-3.3) | 30/58 | 2.0 (1.0-3.9) |
| Ptrend | .0004 | .03 | .004 | |||
| sVEGFR2 | ||||||
| <10 043.05 | 77/54 | 1.0 | 43/28 | 1.0 | 34/26 | 1.0 |
| 10 043.05-11 279.22 | 74/57 | 1.2 (0.7-1.9) | 35/29 | 1.2 (0.6-2.5) | 39/28 | 1.1 (0.5-2.3) |
| 11 279.23-13 357.80 | 75/87 | 1.9 (1.1-3.1) | 36/43 | 2.0 (1.0-3.9) | 39/44 | 1.7 (0.8-3.7) |
| ≥13 357.81 | 75/103 | 2.3 (1.4-3.9) | 39/53 | 2.3 (1.2-4.6) | 36/50 | 2.3 (1.0-5.1) |
| Ptrend | .0005 | .01 | .02 | |||
| IL-16 | ||||||
| <13.60 | 76/51 | 1.0 | 31/23 | 1.0 | 44/28 | 1.0 |
| 13.60-24.89 | 76/77 | 1.5 (0.9-2.5) | 39/40 | 1.4 (0.7-2.9) | 38/37 | 1.6 (0.8-3.2) |
| 24.90-35.26 | 74/74 | 1.6 (1.0-2.7) | 42/39 | 1.3 (0.6-2.9) | 33/35 | 1.9 (0.9-3.9) |
| ≥35.27 | 75/99 | 2.1 (1.3-3.3) | 41/51 | 1.7 (0.8-3.5) | 34/48 | 2.4 (1.2-4.7) |
| Ptrend | .006 | .15 | .02 | |||
| TRAIL | ||||||
| <24.09 | 76/68 | 1.0 | 35/42 | 1.0 | 41/26 | 1.0 |
| 24.09-31.40 | 75/48 | 0.7 (0.4-1.2) | 36/28 | 0.6 (0.3-1.3) | 39/20 | 0.8 (0.4-1.7) |
| 31.41-41.95 | 75/80 | 1.2 (0.8-1.9) | 39/35 | 0.8 (0.4-1.4) | 36/45 | 2.2 (1.1-4.4) |
| ≥41.96 | 75/105 | 1.6 (1.0-2.5) | 43/48 | 0.9 (0.5-1.7) | 32/57 | 2.8 (1.4-5.6) |
| Ptrend | .009 | .95 | .0004 | |||
| Amylin | ||||||
| <LLOD | 171/148 | 1.0 | 82/76 | 1.0 | 89/72 | 1.0 |
| Detectable | 130/153 | 1.5 (1.0-2.1) | 71/77 | 1.2 (0.7-1.9) | 59/76 | 1.9 (1.1-3.2) |
| P§ | .04 | .46 | .03 | |||
| Analyte concentration (pg/mL)* . | . | . | . | Years from blood collection to case diagnosis . | ||
|---|---|---|---|---|---|---|
| Overall . | 5-7 . | 8-13 . | ||||
| NCont/NCase . | OR† (95% CI) . | NCont/NCase . | OR† (95% CI) . | NCont/NCase . | OR† (95% CI) . | |
| BCA-1 | ||||||
| <12.44 | 76/52 | 1.0 | 29/28 | 1.0 | 47/24 | 1.0 |
| 12.44-15.56 | 75/52 | 1.0 (0.6-1.6) | 36/26 | 0.8 (0.4-1.7) | 39/26 | 1.1 (0.6-2.3) |
| 15.57-20.15 | 75/61 | 1.3 (0.8-2.1) | 46/29 | 0.6 (0.3-1.4) | 29/32 | 2.2 (1.1-4.6) |
| ≥20.16 | 75/136 | 2.7 (1.7-4.2) | 42/70 | 1.7 (0.9-3.5) | 33/66 | 3.7 (1.9-7.2) |
| Ptrend‡ | 1.0 × 10−6 | .007 | 3.8 × 10−5 | |||
| sTNFR2 | ||||||
| <4021.67 | 76/45 | 1.0 | 37/25 | 1.0 | 39/20 | 1.0 |
| 4021.67-4896.02 | 75/52 | 1.3 (0.8-2.3) | 36/22 | 1.0 (0.5-2.2) | 39/30 | 1.7 (0.8-3.6) |
| 4896.03-5792.83 | 75/82 | 2.1 (1.2-3.5) | 37/42 | 2.0 (1.0-4.3) | 38/40 | 2.2 (1.0-4.6) |
| ≥5792.84 | 75/122 | 3.4 (2.0-5.8) | 43/64 | 3.1 (1.4-6.7) | 32/58 | 3.8 (1.8-8.1) |
| Ptrend | 1.1 × 10−6 | .001 | .0003 | |||
| TNF-α | ||||||
| <4.07 | 76/68 | 1.0 | 39/32 | 1.0 | 37/36 | 1.0 |
| 4.07-5.03 | 75/41 | 0.6 (0.4-1.1) | 34/21 | 0.8 (0.4-1.7) | 41/20 | 0.5 (0.2-1.0) |
| 5.04-6.35 | 75/74 | 1.2 (0.7-1.9) | 35/40 | 1.4 (0.7-2.8) | 40/34 | 0.5 (0.2-1.0) |
| ≥6.36 | 75/118 | 1.8 (1.1-2.9) | 45/60 | 1.7 (0.9-3.3) | 30/58 | 2.0 (1.0-3.9) |
| Ptrend | .0004 | .03 | .004 | |||
| sVEGFR2 | ||||||
| <10 043.05 | 77/54 | 1.0 | 43/28 | 1.0 | 34/26 | 1.0 |
| 10 043.05-11 279.22 | 74/57 | 1.2 (0.7-1.9) | 35/29 | 1.2 (0.6-2.5) | 39/28 | 1.1 (0.5-2.3) |
| 11 279.23-13 357.80 | 75/87 | 1.9 (1.1-3.1) | 36/43 | 2.0 (1.0-3.9) | 39/44 | 1.7 (0.8-3.7) |
| ≥13 357.81 | 75/103 | 2.3 (1.4-3.9) | 39/53 | 2.3 (1.2-4.6) | 36/50 | 2.3 (1.0-5.1) |
| Ptrend | .0005 | .01 | .02 | |||
| IL-16 | ||||||
| <13.60 | 76/51 | 1.0 | 31/23 | 1.0 | 44/28 | 1.0 |
| 13.60-24.89 | 76/77 | 1.5 (0.9-2.5) | 39/40 | 1.4 (0.7-2.9) | 38/37 | 1.6 (0.8-3.2) |
| 24.90-35.26 | 74/74 | 1.6 (1.0-2.7) | 42/39 | 1.3 (0.6-2.9) | 33/35 | 1.9 (0.9-3.9) |
| ≥35.27 | 75/99 | 2.1 (1.3-3.3) | 41/51 | 1.7 (0.8-3.5) | 34/48 | 2.4 (1.2-4.7) |
| Ptrend | .006 | .15 | .02 | |||
| TRAIL | ||||||
| <24.09 | 76/68 | 1.0 | 35/42 | 1.0 | 41/26 | 1.0 |
| 24.09-31.40 | 75/48 | 0.7 (0.4-1.2) | 36/28 | 0.6 (0.3-1.3) | 39/20 | 0.8 (0.4-1.7) |
| 31.41-41.95 | 75/80 | 1.2 (0.8-1.9) | 39/35 | 0.8 (0.4-1.4) | 36/45 | 2.2 (1.1-4.4) |
| ≥41.96 | 75/105 | 1.6 (1.0-2.5) | 43/48 | 0.9 (0.5-1.7) | 32/57 | 2.8 (1.4-5.6) |
| Ptrend | .009 | .95 | .0004 | |||
| Amylin | ||||||
| <LLOD | 171/148 | 1.0 | 82/76 | 1.0 | 89/72 | 1.0 |
| Detectable | 130/153 | 1.5 (1.0-2.1) | 71/77 | 1.2 (0.7-1.9) | 59/76 | 1.9 (1.1-3.2) |
| P§ | .04 | .46 | .03 | |||
CI, confidence interval; LLOD, lower limit of detection; NCont, number of controls; NCase, number of cases; OR, odds ratio.
Analyte concentrations categorized using quartiles among all controls as cutpoints.
Odds ratios computed using conditional logistic regression.
Wald test from regression analysis modeling analyte intra-category medians as a continuous variable.
Wald test P value from regression analysis modeling analyte as dichotomized variable (<LLOD, detectable).